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Abstract
Background: A reduction in the number of podocytes and podocyte density has been
documented in the kidneys of patients with diabetes mellitus. Additional studies have shown that
podocyte injury and loss occurs in both diabetic animals and humans. However, most studies in
animals have examined relatively long-term changes in podocyte number and density and have not
examined effects early after initiation of diabetes. We hypothesized that streptozotocin diabetes in
rats and mice would result in an early reduction in podocyte density and that this reduction would
be prevented by antioxidants.
Methods: The number of podocytes per glomerular section and the podocyte density in glomeruli
from rats and mice with streptozotocin (STZ)-diabetes mellitus was determined at several time
points based on detection of the glomerular podocyte specific antigens, WT-1 and GLEPP1. The
effect of insulin administration or treatment with the antioxidant, α-lipoic acid, on podocyte
number was assessed.
Results: Experimental diabetes resulted in a rapid decline in apparent podocyte number and
podocyte density. A significant reduction in podocytes/glomerular cross-section was found in STZ
diabetes in rats at 2 weeks (14%), 6 weeks (18%) and 8 weeks (34%) following STZ injection. Similar
declines in apparent podocyte number were found in STZ diabetes in C57BL/6 mice at 2 weeks,
but not at 3 days after injection. Treatment with α-lipoic acid substantially prevented podocyte loss
in diabetic rats but treatment with insulin had only a modest effect.
Conclusion: STZ diabetes results in reduction in apparent podocyte number and in podocyte
density within 2 weeks after onset of hyperglycemia. Prevention of these effects with antioxidant
therapy suggests that this early reduction in podocyte density is due in part to increased levels of
reactive oxygen species as well as hyperglycemia.
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The clinical hallmarks of diabetic nephropathy include
progressive albuminuria followed by a gradual decline in
renal function concluding, after 5–15 years, with end-
stage renal disease. Glomerular basement thickening and
mesangial expansion, due to accumulation of extracellu-
lar matrix proteins, have been identified as pathological
precursors of these clinical changes [1]. In the last few
years, several reports have suggested that loss of glomeru-
lar epithelial cells, or podocytes, precedes and predicts the
onset of clinical nephropathy and may be an early patho-
logical manifestation of diabetic nephropathy [2-4].
Moreover, it has been postulated that the loss of podo-
cytes could be pathogenically important in leading to
glomerular scarring and albuminuria [5].
Meyer and colleagues first showed that podocyte number
was reduced in Type 2 diabetic Pima Indian patients. They
found that podocytes were decreased in those subjects
with microalbuminuria and even more profoundly
decreased in those with overt DN [2]. In a prospective fol-
low-up analysis the same authors demonstrated that orig-
inal podocyte number predicted the rate of increase in
albuminuria; those patients with the smallest number of
podocytes per glomerulus developed greater increases in
albuminuria over a four year period [3]. In a multi-insti-
tutional cross-sectional study, Steffes et al. also noted that
podocyte number was decreased in patients with Type 1
diabetes [6]. In addition, a report on patients with Type 1
diabetes also showed a decline in podocyte number as
nephropathy progressed. However, the number of podo-
cytes was not significantly decreased early in the develop-
ment of nephropathy nor did it clearly predict the
progression of albuminuria. Podocyte loss correlated with
increasing albuminuria at follow-up, suggesting that both
processes occurred concomitantly [7]. Thus, it remains
unclear whether podocyte loss actually precedes or
accompanies other early changes of diabetic nephropathy.
Moreover, it is uncertain whether podocyte loss actually
promotes progression of the disease or is merely a marker
thereof.
Studies of podocyte loss in early experimental diabetic
animals would provide an avenue for addressing these
questions. Therefore, we assessed apparent podocyte
number and density in diabetic rats and mice and at early
timepoints. Moreover, we determined whether early treat-
ment with insulin or with the antioxidant, α-lipoic acid,
resulted in preservation of podocyte density in animals
with early diabetes.
Methods
Experimental models
The procedures used in this study are in accordance with
the guidelines of the University of Michigan Committee
on the Use and Care of Animals. Veterinary care was pro-
vided by the University of Michigan Unit for Laboratory
Animal Medicine. The University of Michigan is accred-
ited by the American Association of laboratory Animal
Care. The animal care and use program conformed to the
standards in "The Guide for the Care and Use of labora-
tory Animals," Department of Health, Education, and
Welfare Publication No. (NIH) 86-23.
Barrier-sustained Cesarean-delivered male Wistar rats
(Harlan, Indianapolis, IN) weighing 200 to 300 g were
used. Animals were allowed to acclimatize to their envi-
ronment for a week before injection. All animals were
fasted overnight. Rats in the diabetic group were injected
with 50 mg/kg streptozotocin (STZ; Sigma Chemical Co.,
St. Louis, MO) intraperitoneally while control rats
received buffer only. STZ was freshly prepared in 10 mM
citrate buffer, pH 5.5 and used within 10 minutes. Rats
receiving STZ were given 10% sucrose water in the first 48
hrs after injection to prevent hypoglycemia. Diabetes was
confirmed by tail blood glucose levels. Only rats with fast-
ing blood sugar concentrations greater than 300 mg/dl
were utilized for the studies. Four separate studies were
performed. In the first trial, the effect of STZ diabetes on
podocyte number was determined. In experiment two and
three, the effect of insulin administration on podocyte
number was assessed. In these trials, NPH insulin (1.3
units kg-1 day-1) (Eli Lilly and Company, Indianapolis, IN)
was injected subcutaneously twice daily (7 AM and 7 PM)
beginning three days after STZ treatment and continued
for either 2 or 6 weeks. In trial four, the effect of α-lipoic
acid on podocyte loss was assessed. In this trial, 100 mg
kg-1day-1 DL-α-lipoic acid (Sigma) was administered
intraperitoneally to a group of STZ diabetic rats starting 48
hours after STZ injection.
For the mouse diabetes experiments, male 6 week-old
C57BL/6J mice (Jackson Laboratory, Bar Harbor, Maine)
were used. Mice were allowed to acclimate to their envi-
ronment for 3 days before injection. Mice were fasted for
4 hours and then injected intraperitoneally with 50 mg/kg
STZ daily for five consecutive days. Timing of endpoints
for the mouse experiments started the day after the final
STZ injection.
For both mouse and rat experiments, glucose was meas-
ured from a drop of whole blood obtained via the tail vein
(HemoCue Glucose Analyzer, Mission Viejo, CA).
Immunohistochemical analyses
With the rat or mouse under general anesthesia, kidneys
were perfused with freshly made PLP fixative (2% parafor-
maldehyde, 37.5 mM sodium phosphate, pH 7.4, 60 mM
L-lysine and 100 mM sodium m-periodate) under con-
stant 100 mmHg pressure via cardiac puncture or throughPage 2 of 11
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ered saline. Kidney cortical regions were dissected and
placed into PLP fixative. For the lipoic acid trial, kidney
cortical sections were snap-frozen in liquid nitrogen and
stored at -70°C prior to fixation.
Sections (3.9 µm-thick) were cut from the PLP-fixed, par-
affin embedded kidney samples. These sections were
deparaffinized and rehydrated through ethanols (70, 95,
100%). Cryosections (4 µm) from the kidneys obtained
from the lipoic acid trial were brought to room tempera-
ture and air dried. They were then fixed with pre-chilled (-
20°C) acetone for 5 minutes, on ice, and then washed
twice with PBS. All sections were incubated in Retrieve
One buffer (Signet Laboratories, Inc., Dedham, Massa-
chusetts) at 90°C for two hours to enhance antigen
retrieval. Using an ABC Staining Kit (Vector Laboratory
Inc., Dedham, MA), podocyte nuclei were detected with a
rabbit polyclonal or a mouse monoclonal anti-WT1 anti-
body (SantaCruz Biotechnology, Inc., Santa Cruz, CA) at
a concentration of 2 µg/ml. One set of slides was stained
with an antibody to GLEPP1, a podocyte plasma mem-
brane protein, at a concentration of 1/200. The slides for
GLEPP1 detection were counterstained with PAS (Periodic
acid- Schiff reagent).
Morphometric analysis
Images from at least 12 sequential glomerular 3.9 µm
thick cross sections at approximately the glomerular equa-
tor were collected for each histologic section using the
MetaMorph Image System (Universal Imaging Corpora-
tion; Downingtown, PA) by a blinded observer, as previ-
ously reported [5,10]. The mean area of each glomerular
profile was measured by manually tracing the glomerular
outline on a video screen or encircling the area of interest
and calculating that area by computerized morphometry
using the Image Measurement System (Jandel Sigma Scan
3.0, USA) or MetaMorph 4.69. The numbers of podocytes
per glomerular section and glomerular volume/podocyte
(µm3) as defined by WT1 or GLEPP1 immunoperoxidase
staining was determined. The latter number was calcu-
lated as determined in the morphometric analysis of
podocyte counting methods by Sanden et al [10]. We uti-
lized identical methods and equipment and utilized the
uncorrected glomerular volume/podocyte (Column H,
table 1 in reference ) as reported in that study. GV/P is a
variable that incorporates the relationship between both
podocyte number and GBM surface area and therefore
should be a useful measure of the degree of podocyte
reserve [10] and is the reciprocal of podocyte density.
Data analysis
Data are presented as means ± standard error of the mean.
When comparing 2 groups, a Student's t-test was used. For
multiple comparisons, an ANOVA followed by Scheffe's
post-hoc analysis was performed. P values ≤ 0.05 were
considered statistically significant.
Results
STZ diabetes was induced conventionally in male rats. The
rats developed sustained hyperglycemia compared to con-
trol rats (Table 1). Subsets of diabetic rats received twice
daily insulin for 2, 6 or 8 weeks. Fasting blood glucose lev-
els in insulin-treated rats were significantly lower than
untreated STZ-diabetic rats but were still elevated above
control values until 2 weeks after initiation of insulin
administration. All rats gained weight during the study,
although the untreated diabetic rats were statistically
lighter than both the control and insulin-treated animals
by the end of 2 and 6 weeks (Table 1).
Table 1: STZ Rat Characteristics
Blood glucose concentrations (mg/dl) Body weight (g)
Day 0 Day 3 Day 7 Day 14 End Day 3 End
Trial 1 (8 wks) Control 78 ± 5 68 ± 5 270 ± 7 426 ± 18
STZ 357 ± 24 365 ± 12 237 ± 5 297 ± 18
Trial 2 (2 wks) Control 53 ± 3 75 ± 5 76 ± 4 62 ± 4 302 ± 3 359 ± 5
STZ 49 ± 1 363 ± 17 357 ± 24 297 ± 20 274 ± 7 299 ± 9
STZ + Ins 49 ± 2 147 ± 46 104 ± 38 43 ± 1 290 ± 6 356 ± 7
Trial 3 (6 wks) Control 51 ± 1 74 ± 4 77 ± 3 65 ± 4 68 ± 3 314 ± 4 467 ± 12
STZ 48 ± 1 348 ± 23 315 ± 43 305 ± 32 300 ± 6 276 ± 4 347 ± 18
STZ + Ins 48 ± 2 214 ± 35 60 ± 21 47 ± 3 69 ± 16 278 ± 5 450 ± 6
Trial 4 (6 wks) Control N/A 65 ± 7 N/A 455 ± 27
STZ 377 ± 10 340 ± 60 318 ± 3 327 ± 51
STZ + LA 369 ± 13 322 ± 44 304 ± 4 306 ± 32Page 3 of 11
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number as determined by staining for WT1 and GLEPP1
(Fig 1). Podocyte number in STZ diabetes was assessed at
3 time points, 2, 6 and 8 weeks following STZ injection
(Fig. 2). Apparent podocyte number, expressed as podo-
cytes/glomerular section was decreased and glomerular
volume/podocyte (GV/P) was concomitantly increased in
the diabetic rats as early as 2 weeks after STZ injection.
When compared to control rats, there was a 14% decline
in podocyte number/glomerular section and a 33% recip-
rocal increase in glomerular volume/podocyte (GV/P)
after 2 weeks of diabetes (Fig 2). Similar though some-
what more profound podocyte loss and increase in GV/P
were detected in diabetic rats 6 and 8 weeks after STZ
injection (Fig 2).
Male C57BL/6 mice were made diabetic with repeated low
dose STZ injection. Their weights and glucose concentra-
tions are displayed in Table 2. As in the rat model, these
diabetic mice showed a decline in podocyte number 2
weeks after the final STZ injection (Fig. 3). There was a
15% decline in the number of podocytes per glomerular
section and a 15% increase in GV/P at 2 weeks after the
end of the STZ injection period. Importantly, there was no
difference in podocyte numbers in streptozotocin-treated
mice 3 days after the end of the 5-day STZ injection proto-
col (Fig 3). This strongly suggests that STZ does not have
a direct toxic effect on podocytes in this model.
Additionally, at both 2 and 6 weeks post STZ injection,
diabetic rats treated with insulin showed an intermediate
phenotype between normal and diabetic rats that did not
receive insulin treatment (Figs. 4 and 5). Thus, insulin
treatment appeared to prevent some of the reduction in
podocyte density accompanying STZ diabetes. Daily treat-
ment with α-lipoic acid had a more substantial normaliz-
ing effect on podocytes/glomerular section and GV/P.
Diabetic rats receiving this agent, while similarly hyperg-
lycemic to diabetic rats that did not receive it, had almost
normal numbers of podocytes per glomerular section and
GV/P (Fig. 6).
Discussion
In the current study we have determined that podocyte
density and apparent glomerular podocyte number are
substantially reduced in rats and mice injected with STZ, a
model of Type 1 diabetes mellitus, quite early after initia-
tion of diabetes. Reduction in apparent podocyte  number
and podocyte density occurred as early as 2 weeks after
STZ  injection, and appeared to worsen somewhat by 6
and even further by 8  weeks after STZ administration.
Importantly, STZ did not appear to have an acute toxic
Immunohistological detection of WT1 in control and STZ-diabetic rat glomeruliFigure 1
Immunohistological detection of WT1 in control and STZ-diabetic rat glomeruli. Podocytes were detected with antibodies to 
WT1. WT1 staining is indicated by intense immunoperoxidase activity in podocyte nuclei (arrows).
WT1
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Podocyte number at 2, 6 and 8 weeks after STZ injection in ratsFigure 2
Podocyte number at 2, 6 and 8 weeks after STZ injection in rats. Data are presented as numbers of podocytes per glomerular 
section and of glomerular volume per podocyte (GV/P [µm3]). * = p < 0.01, and ** = p < 0.001 vs. control animals. N = 6 ani-
mals per group.
BMC Nephrology 2006, 7:6 http://www.biomedcentral.com/1471-2369/7/6effect on podocytes, at least in the murine model, since 3
days after completion of the five day STZ injection proto-
col apparent podocyte number and density was com-
pletely normal in STZ treated mice. Also significantly,
insulin treatment had only a modest effect in maintaining
podocyte number, despite inducing a substantial
improvement in fasting blood glucose levels by 2 weeks
after initiation of diabetes. In contrast, administration of
the antioxidant, α-lipoic acid was more effective in main-
taining podocyte number and density. These latter data
suggest that near normalization of glucose levels, even as
early as 2 weeks after initiation of STZ-diabetes, cannot
fully prevent the reduction in podocyte number, possibly
because the early effects of hyperglycemia are dominant in
this model. In addition, the protection with α-lipoic acid
suggests that oxidant-mediated injury plays a role in the
Table 2: STZ Mouse Characteristics
Blood glucose (mg/dl) Body weight (g)
3 days 2 weeks 3 days 2 weeks
Control 133.5 ± 5.4 123.2 ± 5.1 25.8 ± 0.3 27.8 ± 0.4
STZ 171.8 ± 10.2 303.4 ± 16.5 23.5 ± 0.4 25.0 ± 0.6
Podocyte number at 3 days and 2 weeks after end of the 5 day STZ injection protocol in miceFigure 3
Podocyte number at 3 days and 2 weeks after end of the 5 day STZ injection protocol in mice. Data are presented as numbers 
of podocytes per glomerular section and of glomerular volume pre podocyte (GV/P [µm3]). * = p < 0.05 vs. control animals. N 
= 5 animals per group.
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BMC Nephrology 2006, 7:6 http://www.biomedcentral.com/1471-2369/7/6early diminution in podocyte density consistent with
other effects of oxidants in mediating or enhancing dia-
betic complications [e.g., [12]].
Our methods of podocyte counting relied on accurately
identifying podocyte nuclei (WT-1) or cytoplasm
(GLEPP1). The WT-1 staining tends to be more precise
since it is difficult to distinguish the cytoplasmic extent of
any single podocyte using these methods. As noted by
these investigators, a  potential disadvantage of this
method is that podocyte nuclei are  not uniformly WT-1
positive under some pathologic circumstances [10]. As
noted by these investigators, a potentially disadvantage of
this method is that podocyte nuclei are not uniformly WT-
1 positive under some pathologic circumstances ([10]).
However, as they also noted, there are no data to indicate
that podocytes in DN are WT-1 negative. In addition, WT-
1 is an excellent marker of the normal mature differenti-
ated podocyte and even podocytes with effaced foot proc-
esses remain WT-1 positive. Hence, if a podocyte is WT-1
negative, then it is likely to be severely and perhaps termi-
nally damaged. Thus, we believe that our data are consist-
ent with true and quite early reductions in podocyte
density in experimental diabetic nephropathy and at the
least reflect severe podocyte damage.
Although the morphometric methods utilized in this
study are somewhat different from those developed by
Weibel and Gomez and Cavalieri, they clearly assess very
similar parameters and have been well validated in the
previous publications [5,10]. Nonetheless, since we did
not survey glomerular serial sections in these studies, nor
investigate both thick and thin sections of the same
glomerulus, we cannot claim that we have demonstrated
an absolute reduction in numbers of podocytes/glomeru-
lus. The increase in glomerular size in diabetes may have
contributed to the reduction in podocytes/glomerular sec-
tion. However, it is clear that glomerular density was sub-
stantially reduced and the glomerular volume subsumed
by each podocyte was increased in these Type 1 diabetic
models. Although there appears to be a great deal of pre-
cision using these methods, as noted by the small vari-
ances in each study, there was a substantially greater
reduction in apparent podocyte number after 8 weeks
than after 6 weeks of STZ-diabetes (34 vs. 18 %). Whether
this represents true continued podocyte loss over the
intervening time period is uncertain, and would need to
be validated by a larger single trial in which all animals
were made diabetic at the same time followed by assess-
ment of podocyte loss in samples at regular intervals.
Previously, several studies in Type 1 and Type 2 diabetic
patients have suggested that diabetes leads to a reduction
in glomerular podocyte number as a relatively early
marker of diabetic nephropathy [2-4,6]. Moreover, Meyer
and colleagues showed that the number of podocytes per
glomerulus at the start of the study was predictive of the
degree of albuminuria after a four year follow-up, suggest-
Podocyte number at 2 weeks after STZ injection in ratsFigure 4
Podocyte number at 2 weeks after STZ injection in rats. Diab. + ins. = data for diabetic rats that received twice daily insulin 
injections beginning 3 days after STZ injection. Data are presented as numbers of podocytes per glomerular section and of 
glomerular volume pre podocyte (GV/P [µm3]). ** = p < 0.001 vs. control animals. N = 6 animals per group.
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BMC Nephrology 2006, 7:6 http://www.biomedcentral.com/1471-2369/7/6ing that podocyte loss precedes and predicts progressive
diabetic nephropathy [3]. More recently, in a study of Ital-
ian patients with Type 2 diabetes mellitus, substantial
abnormalities in podocyte structure and density were
found to occur during the early stages of diabetic neph-
ropathy [13]. Specifically, glomerular podocyte density
declined early in diabetes and correlated inversely with
albumin excretion rates, although the number of podo-
cytes per glomerulus did not correlate with progression of
disease. These findings prompted the authors to conclude
that the density, not the absolute number, of podocytes
may be important for the progression of nephropathy in
Type 2 patients. In a report by Steffes et al., for the Inter-
national Diabetic Nephropathy Study Group, Type 1 dia-
betic patients were found to have a significantly lower
number of podocytes than age-matched control subjects
[6]. A more recent study has also shown that podocyte loss
accompanies Type 1 diabetes but that this podocyte loss
did not appear to occur as early as in Type 2 patients [7].
Although it reported that podocyte number was lower in
diabetic patients than in nondiabetic controls and that the
surface covered by each podocyte increased gradually with
time, the absolute number of podocytes did not predict
the degree of albuminuria. Nonetheless, in the longitudi-
nal component of the study, there was a significant corre-
lation between the decrease in podocyte number and the
degree of albuminuria over the period from the baseline
observation to follow-up three years later [7]. From all of
these human studies, it remains impossible to conclude
whether decreased podocyte number or density actually
Podocyte number at 6 weeks after STZ injection in ratsFigure 5
Podocyte number at 6 weeks after STZ injection in rats. Diab. + ins. = data for diabetic rats that received twice daily insulin 
injections beginning 3 days after STZ injection. Data are presented as numbers of podocytes per glomerular section and of 
glomerular volume pre podocyte (GV/P [µm3]). Six week trial data were combined for this analysis. N = 11 (Control), 10 (Dia-
betes) or 6 (Diab. + ins). Staining for both WT1 and GLEPP1 is displayed. * = p < 0.05, ** = p < 0.0001
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ropathy or whether the podocyte changes and albuminu-
ria are simply associated findings.
Since the human studies cannot ascertain whether the
decrease in podocyte number causes or simply correlates
with advancing albuminuria and nephropathy, it would
be beneficial to identify animal models that recapitulate
similar changes. Such models would aid the investigation
of the mechanisms by which diabetes results in podocyte
loss and allow determination of whether podocyte loss
directly results in albuminuria. The early podocyte loss
that occurs in humans with diabetic nephropathy appears
to occur quite early in both rat and mouse STZ diabetes.
While the changes are more profound in the rat models,
similar although less substantial reductions in podocyte
density occur in mice after only 2 weeks of STZ diabetes.
Although the current study is the first to show that exper-
imental murine and rat models of diabetes undergo very
early podocyte loss, several previous studies using experi-
mental models of diabetes have demonstrated podocyte
loss or abnormalities after longer periods of diabetes.
Gross and colleagues have shown that similar reduction
in podocytes occurs after 6 months of streptozotocin
(STZ) diabetes in rats [14] and that loss of podocytes in
this model was prevented by treatment with the angi-
otensin converting enzyme inhibitor, trandolopril. In a
separate study, these investigators also showed substantial
podocyte loss after 6 months of diabetes in the SHR/N-cp
rat, a model of type II diabetes that spontaneously devel-
ops pronounced abnormalities in renal histology. In com-
parison to STZ-diabetic rats, which develop relatively
modest glomerular changes at 6 months of diabetes,
glomeruli from the SHR/Ncp rats contained fewer and
larger podocytes, smaller mesangial cells and a more
expanded mesangial matrix [15].
Mifsud and colleagues did not examine podocyte number
but documented that the number of slit pores per unit
length of glomerular basement membrane in rat glomer-
uli was decreased 24 weeks after STZ injection, consistent
with podocyte foot process broadening [9]. These
changes, as well as the increased albumin excretion seen
in this model, were also ameliorated by treatment with
either an angiotensin receptor blocker or an angiotensin
converting enzyme inhibitor [9]. Gassler and colleagues
studied nephron degeneration in Zucker fa/fa male rats, a
model of Type 2 diabetes, at 10 months of age and con-
cluded that degeneration began with damage to podo-
cytes [16]. They demonstrated sclerosis in approximately
25% of the diabetic glomeruli and found evidence of
more extensive, "pre-sclerotic" podocyte injury including
foot process effacement, pseudocyst formation, and accu-
mulation of lysosomal granules and lipid droplets in
podocyte cytoplasm. These podocyte changes appeared to
play a significant role in the progression of the segmental
glomerular injury to global sclerosis as well as to the
degeneration of the corresponding tubule. Hoshi and col-
Podocyte number at 6 weeks after STZ injection in ratsFigure 6
Podocyte number at 6 weeks after STZ injection in rats. Diab. + LA = data for diabetic rats that received daily α-lipoic acid 
injections beginning 2 days after STZ injection. Data are presented as numbers of podocytes per glomerular section and of 
glomerular volume pre podocyte (GV/P [µm3]). * = p < 0.05; ** = p < 0.001. N = 5 animals per group except in Diabetes group 
which was 4 animals.
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BMC Nephrology 2006, 7:6 http://www.biomedcentral.com/1471-2369/7/6leagues also found electron microscopic evidence of
podocyte degeneration and the development of tuft adhe-
sions that they concluded were responsible for the
glomerular sclerosis in the same model [8].
In addition, several studies have found that diabetes was
associated with a significant reduction in expression of the
podocyte slit diaphragm protein, nephrin, in both human
[17] and animal models [18] of diabetes. However, in the
studies in STZ diabetes in rats there was no change in
nephrin expression after one week of diabetes [17]. Since
our data indicate that podocyte changes occur quite early
in STZ diabetes and is statistically significant as early as 2
weeks after induction of diabetes, it seems likely that the
change in nephrin expression was either a response to
podocyte injury or stress, or developed independently of
the early podocyte changes found in this model.
The biochemical and metabolic signals that result in dia-
betic glomerulopathy have been the subject of investiga-
tion over the past several decades. A unifying factor in
promoting most if not all of the abnormalities found in
the diabetic glomerulus appears to be the increase in
mitochondrial oxidative stress generated by enhanced
glucose metabolic flux [19,20]. For these studies, we used
a potent inhibitor of mitochondrial superoxide genera-
tion, α-lipoic acid, which virtually eliminated the effects
of STZ-diabetes on reduction in podocyte density and
apparent number, supporting the notion that mitochon-
drial reactive oxygen species are critical in these early
changes of diabetic glomerulopathy.
Since STZ also has nephrotoxic effects, especially when
given at high doses, it is conceivable that STZ had a direct
toxic effect on podocytes and that some of the effect of α-
lipoic acid was to protect against such toxicity. While our
studies do not absolutely rule this out, we feel this is
unlikely for several reasons: 1) other models of diabetic
nephropathy that arise spontaneously show similar
decreases in podocyte number and density [e.g., [15]]; 2)
relatively low dose STZ as used in these experiments has
not been associated with proximal tubule toxicity and the
proximal tubule cell should be especially sensitive to STZ
since, like the pancreatic β cell, it expresses high levels of
the facilitative glucose transporter, GLUT2 which trans-
ports STZ into cells [21], 3) finally and most importantly,
we demonstrated that no changes in podocyte density or
apparent number occurred within 3 days after completion
of a 5-day low dose STZ protocol in mice, which strongly
suggests that STZ has no acute podocyte toxicity.
Although the early apparent loss of podocytes in the STZ
diabetic rat and mouse models implicates podocyte dam-
age in the pathogenesis of diabetic nephropathy, it is also
striking that such changes precede albuminuria and
glomerulosclerosis by at least several months. Moreover,
the STZ rat and mouse models, as is true for most animal
models of diabetic complications, fail to develop classic
changes of human diabetic nephropathy. Thus it seems
likely that the early podocyte changes, though important,
may not be sufficient to lead to progressive diabetic neph-
ropathy and renal failure. It may be that a certain thresh-
old of podocyte damage must be achieved before sclerosis
occurs, as suggested by Kim et al. [5]. Conversely, nephro-
sclerosis may be dependent on mesangial and other fac-
tors that are not directly affected by podocyte changes, as
suggested by many studies over the past 20 years (for an
overview, see reference ). Nonetheless, the sensitivity of
the podocyte to hyperglycemic damage is now evident.
These early changes in podocytes may lead to long-term
glomerular responses that are critical for the development
of diabetic nephropathy.
Conclusion
Reduction in podocyte density that occurs in humans
with early diabetic nephropathy is recapitulated in rat and
mouse models of diabetes. Some of this reduction in
podocyte density is likely due to podocyte loss, and can be
prevented by treatment with a powerful antioxidant, sug-
gesting that podocytes undergo oxidant injury quite early
in diabetic kidney disease. It should now be possible to
utilize molecular methods in murine and other animal
models to further determine the mechanisms of early
podocyte damage and the structural and functional seque-
lae of podocyte loss in diabetic nephropathy.
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